TwinBeech Capital’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.5M Buy
+27,700
New +$1.62M 0.58% 50
2025
Q4
– Sell
-50,450
Closed -$590K – 853
2025
Q3
$590K Buy
+50,450
New +$658K 0.02% 374
2025
Q2
– Sell
-18,244
Closed -$159K – 985
2025
Q1
$159K Buy
18,244
+5,739
+46% +$72.3K ﹤0.01% 670
2024
Q4
$180K Buy
+12,505
New +$197K ﹤0.01% 565
2024
Q3
– Sell
-19,015
Closed -$370K – 902
2024
Q2
$370K Buy
+19,015
New +$498K 0.01% 469
2023
Q3
– Sell
-5,521
Closed -$308K – 903
2023
Q2
$308K Buy
+5,521
New +$299K 0.01% 543
2022
Q2
– Sell
-89,975
Closed -$6.84M – 738
2022
Q1
$6.84M Buy
+89,975
New +$7.87M 0.3% 100
2021
Q4
– Sell
-2,606
Closed -$379K – 821
2021
Q3
$379K Buy
+2,606
New +$447K 0.03% 474
2020
Q4
– Sell
-3,151
Closed -$393K – 617
2020
Q3
$393K Buy
+3,151
New +$331K 0.09% 309
2020
Q2
– Sell
-5,435
Closed -$339K – 495
2020
Q1
$339K Buy
+5,435
New +$424K 0.14% 208

Other funds holding TXG

TwinBeech Capital's TXG Position: Q3 2026 in Review

TwinBeech Capital opened a new position in 10x Genomics (TXG) in Q3 2026: 27,700 shares worth $2.5M. The stake represents 0.58% of the portfolio and ranks #50 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in TXG as recently as Q3 2025.

TwinBeech Capital first reported a position in TXG in Q1 2020 and has held it in 10 quarters since. The position peaked at $6.84M in Q1 2022. 491 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • TwinBeech Capital held 27,700 shares of 10x Genomics worth $2.5M as of Q3 2026.
  • 10x Genomics was a new TwinBeech Capital position in Q3 2026.
  • 10x Genomics made up 0.58% of TwinBeech Capital's portfolio in Q3 2026, its #50 holding.
  • TwinBeech Capital first reported a position in 10x Genomics in Q1 2020 and has held it in 10 quarters since.
  • TwinBeech Capital's 10x Genomics position peaked at $6.84M in Q1 2022.
  • 491 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on TwinBeech Capital's 13F filing for Q3 2026, filed 16 Nov 2026.